The clinical value of drug litigation
Executive Summary
Litigation against pharma companies can result in better definition of drug risks, Harvard University Medical School's Aaron Kesselheim and Jerry Avorn argue in a Jan. 17 JAMA article. In several cases involving SSRIs and COX-2s, lawsuits produced useful data that previously had not been publicly released, the authors say. Suits could also motivate "proper disclosure initially by presenting the possibility of substantial damages in cases of misconduct." Describing litigants as "drug safety researchers of last resort," the essay criticizes FDA's effort to pre-empt product liability claims (1"The Pink Sheet" Aug. 28, 2006, p. 7)...
You may also be interested in...
Court Ruling On Preemption Leaves Window Open For False Advertising Suits
FDA's failure to include false advertising claims in its policy on preemption implies that the agency "does not intend its review of promotional materials to preempt false advertising claims," according to a recent federal court decision
European SEAC Opinion Unchanged: Microplastics Must Be Out Of All Cosmetics Within Six Years
The final opinion of ECHA’s Socio-Economic Analysis Committee, published on 1 March, is largely unchanged from its July 2020 draft opinion with regard to microplastic in cosmetic products. That means industry may have to convince EU member state authorities that the restriction proposal has a serious proportionality problem.
QUOTED. 2 March 2021. Michael Coyle.
Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm’s CEO, said about it here.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: